Travere Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 50.57 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.77B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urin...